These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

274 related items for PubMed ID: 9349746

  • 1. Prevalent decrease of the EGF content in the periurethral zone of BPH tissue induced by treatment with finasteride or flutamide.
    Monti S, Sciarra F, Adamo MV, Toscano V, Trotta MC, Martini C, Lanzara S, Silverio FD.
    J Androl; 1997; 18(5):488-94. PubMed ID: 9349746
    [Abstract] [Full Text] [Related]

  • 2. Effects of long-term treatment with Serenoa repens (Permixon) on the concentrations and regional distribution of androgens and epidermal growth factor in benign prostatic hyperplasia.
    Di Silverio F, Monti S, Sciarra A, Varasano PA, Martini C, Lanzara S, D'Eramo G, Di Nicola S, Toscano V.
    Prostate; 1998 Oct 01; 37(2):77-83. PubMed ID: 9759701
    [Abstract] [Full Text] [Related]

  • 3. Androgen concentrations and their receptors in the periurethral region are higher than those of the subcapsular zone in benign prostatic hyperplasia (BPH).
    Monti S, Di Silverio F, Toscano V, Martini C, Lanzara S, Varasano PA, Sciarra F.
    J Androl; 1998 Oct 01; 19(4):428-33. PubMed ID: 9733145
    [Abstract] [Full Text] [Related]

  • 4. Regional variations of insulin-like growth factor I (IGF-I), IGF-II, and receptor type I in benign prostatic hyperplasia tissue and their correlation with intraprostatic androgens.
    Monti S, Di Silverio F, Iraci R, Martini C, Lanzara S, Falasca P, Poggi M, Stigliano A, Sciarra F, Toscano V.
    J Clin Endocrinol Metab; 2001 Apr 01; 86(4):1700-6. PubMed ID: 11297606
    [Abstract] [Full Text] [Related]

  • 5. Regional distribution of epidermal growth factor, testosterone and dihydrotestosterone in benign prostatic hyperplasia tissue.
    Sciarra F, Monti S, Adamo MV, Palma E, Toscano V, d'Eramo G, di Silverio F.
    Urol Res; 1995 Apr 01; 23(6):387-90. PubMed ID: 8788277
    [Abstract] [Full Text] [Related]

  • 6. Evaluation of MENT on primary cell cultures from benign prostatic hyperplasia and prostate carcinoma.
    Mendoza P, Sánchez C, Contreras HR, Vergara J, Acevedo C, Cabezas J, Huidobro C, Noé G, Castellón EA.
    Int J Androl; 2009 Dec 01; 32(6):607-15. PubMed ID: 18637152
    [Abstract] [Full Text] [Related]

  • 7. The concentrations of the endogenous C19-steroids in hyperplastic prostatic tissue and the effect of finasteride treatment.
    Hill M, Petrik R, Hampl R, Stárka L.
    Horm Metab Res; 1996 Oct 01; 28(10):562-4. PubMed ID: 8934217
    [Abstract] [Full Text] [Related]

  • 8. [Measurement of T and DHT contents in normal and diseased human prostate tissues].
    Zhang Y, Ye L, Ding Q, Fang Z, Yao M, Shi D.
    Zhonghua Wai Ke Za Zhi; 2000 Jul 01; 38(7):545-7. PubMed ID: 11832106
    [Abstract] [Full Text] [Related]

  • 9. Comparison of histological compositions and apoptosis in canine spontaneous benign prostatic hyperplasia treated with androgen suppressive agents chlormadinone acetate and finasteride.
    Shibata Y, Fukabori Y, Ito K, Suzuki K, Yamanaka H.
    J Urol; 2001 Jan 01; 165(1):289-93. PubMed ID: 11125427
    [Abstract] [Full Text] [Related]

  • 10. 5alpha-reductase inhibitors/finasteride.
    Stoner E.
    Prostate Suppl; 1996 Jan 01; 6():82-7. PubMed ID: 8630236
    [Abstract] [Full Text] [Related]

  • 11. Differential effect of finasteride on the tissue androgen concentrations in benign prostatic hyperplasia.
    Habib FK, Ross M, Tate R, Chisholm GD.
    Clin Endocrinol (Oxf); 1997 Feb 01; 46(2):137-44. PubMed ID: 9135694
    [Abstract] [Full Text] [Related]

  • 12. [Effect of dutasteride on reduction of plasma DHT following finasteride therapy in patients with benign prostatic hyperplasia].
    Botto H, Lan O, Poulain JE, Comenducci A.
    Prog Urol; 2005 Dec 01; 15(6):1090-5. PubMed ID: 16429658
    [Abstract] [Full Text] [Related]

  • 13. Effect of finasteride, a 5 alpha-reductase inhibitor on prostate tissue androgens and prostate-specific antigen.
    Geller J.
    J Clin Endocrinol Metab; 1990 Dec 01; 71(6):1552-5. PubMed ID: 1699965
    [Abstract] [Full Text] [Related]

  • 14. The effect of dutasteride on intraprostatic dihydrotestosterone concentrations in men with benign prostatic hyperplasia.
    Wurzel R, Ray P, Major-Walker K, Shannon J, Rittmaster R.
    Prostate Cancer Prostatic Dis; 2007 Dec 01; 10(2):149-54. PubMed ID: 17189955
    [Abstract] [Full Text] [Related]

  • 15. Effects of finasteride on vascular endothelial growth factor.
    Häggström S, Tørring N, Møller K, Jensen E, Lund L, Nielsen JE, Bergh A, Damber JE.
    Scand J Urol Nephrol; 2002 Dec 01; 36(3):182-7. PubMed ID: 12201932
    [Abstract] [Full Text] [Related]

  • 16. [Finasteride (Proscar) for benign prostatic hypertrophy].
    Matzkin H, Chen J, Braf Z.
    Harefuah; 1993 Dec 15; 125(12):453-6, 496. PubMed ID: 7509305
    [Abstract] [Full Text] [Related]

  • 17. Effect of dutasteride on intraprostatic androgen levels in men with benign prostatic hyperplasia or prostate cancer.
    Rittmaster R, Hahn RG, Ray P, Shannon JB, Wurzel R.
    Urology; 2008 Oct 15; 72(4):808-12. PubMed ID: 18718641
    [Abstract] [Full Text] [Related]

  • 18. [Hormonal therapy for benign prostatic hyperplasia].
    Sakai H, Kanetake H.
    Nihon Rinsho; 2002 Dec 15; 60 Suppl 11():358-61. PubMed ID: 12599600
    [No Abstract] [Full Text] [Related]

  • 19. Current treatment of BPH.
    Roylance P, Gibelin B, Espié J.
    Biomed Pharmacother; 1995 Dec 15; 49(7-8):332-8. PubMed ID: 8562858
    [Abstract] [Full Text] [Related]

  • 20. [Influence of dihydrotestosterone deficit on treatment of prostatic diseases regarding to contemporary methods of prostatic hypertrophy treatments].
    Laszczyńska M, Chorzepa-Nowicka K, Wylot M, Piasecka M, Gaczarzewicz D.
    Pol Merkur Lekarski; 2008 Dec 15; 25(150):528-30. PubMed ID: 19205388
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.